tailieunhanh - Báo cáo y học: "Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. | Furuse and Hashimoto Annals of General Psychiatry 2010 9 11 http content 9 1 11 ANNALS OF GENERAL PSYCHIATRY CASE REPORT Open Access Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia a potential role of sigma-1 receptors Tsutomu Furuse1 Kenji Hashimoto2 Abstract Background Second-generation antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects EPSs than typical antipsychotic drugs but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Although understanding of the pathophysiology of akathisia remains limited it seems that a complex interplay of several neurotransmitter systems might play a role in its pathophysiology. The endoplasmic reticulum protein sigma-1 receptors are shown to regulate a number of neurotransmitter systems in the brain. Methods We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the akathisia of patients with schizophrenia treated with the antipsychotic drug aripiprazole. Results The global score on the Barnes Akathisia Scale in the two patients with schizophrenia treated with aripiprazole decreased after fluvoxamine monotherapy. Conclusion Doctors may wish to consider fluvoxamine as an alternative approach in treating akathisia associated with antipsychotic drugs such as aripiprazole. Background Second-generation antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects EPSs than typical antipsychotic drugs but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Akathisia is one of the most common and distressing EPSs of antipsychotic drugs 1 2 . The development of akathisia can adversely affect patients adherence to medication and as a consequence have a negative impact on long-term treatment outcomes in patients